# Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-cdk4-6-inhibitors-in-the-first-line-treatment-of-hr-her2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Prajakta P. Masurkar,Haluk Damgacioglu,Ashish A. Deshmukh,Meghana V. Trivedi |
| Citations | 26 |
| DOI | 10.1007/s40273-023-01245-y |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4324311233 |
| PMID | 36920662 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Prajakta P. Masurkar](https://scholariq.org/researchers/prajakta-p-masurkar/)

## Paper journal

- [PharmacoEconomics](https://scholariq.org/journals/pharmacoeconomics/)

## Paper primary topic

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Paper topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.